Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12
Licensing Agreements 13
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13
Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15
Equity Offering 16
Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16
Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18
Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20
Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21
Debt Offering 23
Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23
Asset Transactions 25
Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25
Theravance Biopharma Inc – Key Competitors 26
Theravance Biopharma Inc – Key Employees 27
Theravance Biopharma Inc – Locations And Subsidiaries 28
Head Office 28
Other Locations & Subsidiaries 28
Recent Developments 29
Financial Announcements 29
Nov 06, 2018: Theravance Biopharma reports third quarter 2018 financial results and provides business update 29
Aug 01, 2018: Theravance Biopharma reports second quarter 2018 financial results and provides business update 31
May 08, 2018: Theravance Biopharma Reports First Quarter 2018 Financial Results and Provides Business Update 33
Feb 27, 2018: Theravance Biopharma Announces Fourth Quarter and Full Year 2017 Financial Results 35
Nov 07, 2017: Theravance Biopharma Reports Third Quarter 2017 Financial Results and Provides Business Update 37
Aug 08, 2017: Theravance Biopharma Reports Second Quarter 2017 Financial Results and Provides Business Update 39
May 09, 2017: Theravance Biopharma Reports First Quarter 2017 Financial Results and Provides Business Update 41
Feb 27, 2017: Theravance Biopharma Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update 43
Corporate Communications 45
Jul 31, 2017: Theravance Biopharma Appoints Shehnaaz Suliman, MD, as Senior Vice President of Corporate Development and Strategy 45
Product News 46
05/17/2017: Theravance Biopharma and Mylan to Present Additional Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 46
01/29/2018: Theravance Biopharma and Mylan Announce FDA Acceptance of New Drug Application for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 47
01/23/2017: Theravance Biopharma Reports New Data from Ongoing TOUR Observational Patient Registry in Oral Presentation at SCCM Critical Care Congress 48
01/17/2017: Theravance Biopharma to Present New Data from Ongoing TOUR Observational Patient Registry at SCCM Critical Care Congress 50
Product Approvals 51
Nov 13, 2017: Theravance Biopharma and Mylan Submit New Drug Application to FDA for Revefenacin (TD-4208) in Adults with Chronic Obstructive Pulmonary Disease 51
Clinical Trials 52
Nov 01, 2017: Theravance Biopharma and Mylan Report Additional Positive Phase 3 Data for Revefenacin (TD-4208) in Multiple Presentations at 2017 CHEST Annual Meeting 52
Oct 24, 2017: Theravance Biopharma to Present New Data on Revefenacin (TD-4208) at 2017 CHEST Annual Meeting 54
Jul 19, 2017: Theravance Biopharma and Mylan Announce Positive Results from 12-Month Phase 3 Safety Study of Revefenacin (TD-4208) in Patients with Chronic Obstructive Pulmonary Disease (COPD) 55
May 23, 2017: Theravance Biopharma and Mylan Report Additional Phase 3 Data for Revefenacin (TD-4208) in Several Presentations at 2017 ATS 56
Feb 17, 2017: Theravance Biopharma Presents Positive Clinical Data on TD-1473 at the 12th Congress of the European Crohn’s and Colitis Organization 58
Feb 13, 2017: Theravance Biopharma to Present Clinical Data on TD-1473 at the 12th Congress of the European Crohn’s and Colitis Organization 59
Appendix 60
Methodology 60
About GlobalData 60
Contact Us 60
Disclaimer 60
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Janssen Biotech Enters into Co-Development Agreement with Theravance Biopharma Ireland 11
Theravance Biopharma Enters into Development and Commercialization Agreement with Mylan 12
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 13
Trek Therapeutics Enters into Licensing Agreement with Theravance Biopharma 14
Theravance Biopharma Enters into Co-Development Agreement with SciClone Pharma 15
Theravance Biopharma Raises USD100 Million in Public Offering of Shares 16
Theravance Biopharma Raises USD115 Million in Public Offering of Shares 18
Theravance Biopharma Raises USD23 Million in Private Placement of Shares 20
Theravance Biopharma Raises USD55 Million in Private Placement of Shares 21
Theravance Biopharma Raises USD230 Million in Public Offering of 3.25% Notes Due 2023 23
Cumberland Pharma to Acquire Vibative from Theravance Biopharma 25
Theravance Biopharma Inc, Key Competitors 26
Theravance Biopharma Inc, Key Employees 27
Theravance Biopharma Inc, Subsidiaries 28
List of Figures
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Theravance Biopharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
【免責事項】
http://www.globalresearch.jp/disclaimer